Using a modified natural substance along with current clinical approaches could improve colon cancer treatment, according to findings by the University of California, Irvine biologists. The discovery comes from their research into the role of an amino acid in tumor development and a potential method for reversing the process.
Their study appears in Nature Cancer. Colon cancer is the second-leading cause of cancer-related deaths in the United States.
Eighty-percent of colon cancers stems from a genetic mutation of the protein adenomatous polyposis coli, or APC. While the majority of people with that mutation will develop polyps, only some of the polyps will become cancerous, a phenomenon that is not fully understood. The research team decided to investigate non-genetic factors that could propel the disease, focusing their inquiry on the role of the amino acid glutamine.
“Cancer cells consume a great amount of glutamine to proliferate,” said Mei Kong, associate professor of molecular biology & biochemistry at UCI. “But we found that depriving them of glutamine doesn’t kill all the tumor cells. Some tumor cells are able to adapt and in fact, when their glutamine supply runs low, they turn into a more invasive form of cancer.”
The researchers found that a drop in cellular levels of the metabolite alpha-ketoglutarate after glutamine starvation accompanied the transition from benign to cancerous cells. This finding led them to conduct further investigation into the metabolite’s role. When they provided a modified version of alpha-ketoglutarate to animal models with APC mutations, the results were significant. Just 23 percent of those given the modified metabolite developed rectal bleeding, an indication of intestinal tumors, compared to 90 percent of the animal models who did not receive it. It also curbed tumor growth and protected against disease-associated conditions such as weight loss.
“Supplementation of the modified alpha-ketoglutarate inhibits a key cancer-development signaling pathway in colon cancer cells, turning them into more normal cells,” said researcher Thai Q. Tran, the study’s first author. “What’s also notable is that we administered it by mixing it into drinking water, so it was easy to take and it did not affect overall health.”
The research team would like to investigate the further modification of the metabolite to specifically target colon cancer cells.
“We believe this new knowledge shows great potential for using less-toxic and natural approaches in combination with current therapies to more successfully treat colon cancer while better-protecting patients’ overall wellbeing,” said Kong.
The research was conducted in collaboration with Dr. Marian Waterman’s group in the UCI School of medicine. Support for the research was provided by the National Institutes of Health and the American Cancer Society.
Source: UC Irvine